6AYN

Structure of cetuximab with aminoheptanoic acid-linked N-(3-aminopropyl)-L-arginine meditope variant

Summary for 6AYN

• Entry DOI: 10.2210/pdb6ayn/pdb
• Related: 5id0 6au5
• Descriptor: Cetuximab Fab light chain, Cetuximab Fab heavy chain, Cyclic meditope, ... (4 entities in total)
• Functional Keywords: antibody, anti-egfr, immune system
• Biological source: Mus musculus (Mouse); More
• Cellular location: Secreted : P01834
• Total number of polymer chains: 6
• Total formula weight: 96925.90

Authors

Bzymek, K.P.,Williams, J.C. (deposition date: 2017-09-08, release date: 2017-12-13, Last modification date: 2023-11-15)

Primary citation

Bzymek, K.P.,Ma, Y.,Avery, K.N.,Horne, D.A.,Williams, J.C.
Meditope-Fab interaction: threading the hole.
Acta Crystallogr F Struct Biol Commun, 73:688-694, 2017

PubMed Abstract: Meditope, a cyclic 12-residue peptide, binds to a unique binding side between the light and heavy chains of the cetuximab Fab. In an effort to improve the affinity of the interaction, it was sought to extend the side chain of Arg8 in the meditope, a residue that is accessible from the other side of the meditope binding site, in order to increase the number of interactions. These modifications included an n-butyl and n-octyl extension as well as hydroxyl, amine and carboxyl substitutions. The atomic structures of the complexes and the binding kinetics for each modified meditope indicated that each extension threaded through the Fab `hole' and that the carboxyethylarginine substitution makes a favorable interaction with the Fab, increasing the half-life of the complex by threefold compared with the unmodified meditope. Taken together, these studies provide a basis for the design of additional modifications to enhance the overall affinity of this unique interaction.

PubMed: 29199990
DOI: 10.1107/S2053230X17016272

Experimental method

X-RAY DIFFRACTION (2.48 Å)